Moderna’s Cancer Vaccine Breakthrough Sparks Hope—and a Stock Surge

Moderna’s Cancer Vaccine Breakthrough Sparks Hope—and a Stock Surge
A personalized cancer vaccine has cleared its biggest test yet, giving Moderna a potential post-Covid lifeline while offering melanoma patients a new reason for hope. But the companies have not yet released the full data behind the headline result.

Moderna and Merck said Wednesday that intismeran autogene, an individualized mRNA therapy made from a patient’s own tumor sample, met both primary goals in a Phase 3 trial in high-risk melanoma. The study enrolled 1,137 patients whose tumors had been surgically removed and compared the vaccine-plus-Keytruda regimen with Keytruda alone.

The result marks the first late-stage success for a personalized mRNA cancer vaccine. Patients receiving the combination stayed free of recurrence or cancer spread longer than those receiving Merck’s immunotherapy by itself, the companies said, calling the findings “statistically significant and clinically meaningful.” Earlier data had suggested a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death, though the new Phase 3 figures remain undisclosed.

For Moderna, the clinical readout quickly became a market verdict: its shares more than doubled in early trading, while Merck also rose. Stéphane Bancel, Moderna’s chief executive, cast the trial as proof that a long-held ambition is becoming practical: “We are now helping turn that vision into a reality.”

Merck emphasized the post-surgery setting, where treatment aims to eliminate disease before it returns. Its research chief, Dr. Dean Y. Li, said individualized neoantigen therapies could “redefine” care for completely resected stage IIB-IV melanoma.

Outside the companies, clinician Danish Nagda described the potential impact bluntly: “This potentially doubles it,” referring to recurrence-free survival prospects for advanced melanoma patients. Still, the promise now hinges on the complete dataset, a medical-conference presentation and regulators’ review.

Continue reading https://foxvector.com/stories/01a01bb6-5b94-1c57-714f-336fb69afb96